|
|
1）Mesenchymal stromal cells-derived matrix Gla protein contribute to the alleviation of experimental colitis.Feng Y, Liao Y, Huang W, Lai X, Luo J, Du C, Lin J, Zhang Z, Qiu D, Liu Q, Shen H, Xiang AP*, Zhang Q*. Cell Death Dis. 2018 Jun 7;9(6):691.(IF:5.638)2）Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit.Jiang Y#, Xie J#, Han Z#, Liu W#, Xi S, Huang L, Huang W, Lin T, Zhao LY, Hu YF, Yu J, Zhang Q*, Li T*, Cai SR*, Li G*.Clin Cancer Res. 2018 Jul 24.(IF:10.199) 3）Stanniocalcin-2 contributes to mesenchymal stromal cells attenuating murine contact hypersensitivity mainly via reducing CD8+ Tc1 cells.Chen X#, Liu Q#, Huang W#, Cai C, Xia W, Peng Y, Zheng S, Li G, Xu Y, Wang J, Liu C, Zhang X, Huang L, Xiang AP*, Zhang Q*.Cell Death Dis. 2018;9(5):548.(IF:5.638) 4）Highly efficient and expedited hepatic differentiation from human pluripotent stem cells by pure small-molecule cocktails.Du C#, Feng Y#, Qiu D, Xu Y, Pang M, Cai N, Xiang AP, Zhang Q*.Stem Cell Res Ther. 2018 Mar 9;9(1):58.（IF=4.963） 5）Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma.Cheng Y#, Li H#, Deng Y#*, Tai Y, Zeng K, Zhang Y, Liu W, Zhang Q*, Yang Y*.Cell Death Dis. 2018;9(4):422.(IF:5.638) 6）Aging aggravates hepatic ischemia-reperfusion injury in mice by impairing mitophagy with the involvement of the EIF2α‐parkin pathway. Li Y#, Ruan DY#, Jia CC#, Zheng J, Wang GY, Zhao H, Yang Q, Liu W, Yi SH, Li H, Wang GS, Yang Y, Chen GH*, Zhang Q*. Aging (Albany NY). 2018,10(8):1902-1920. (IF:5.179) 7）Interleukin-17-producing neutrophils link inflammatory stimuli to disease progression by promoting angiogenesis in gastric cancer. Li TJ※, Jiang Y※, Hu YF※, Huang L, Yu J, Zhao LY, Deng HJ, Mou TY, Liu H, Yang Y*, Zhang Q*, Li G*. Clin Cancer Res. 2017, 23(6):1575-1585.(IF:10.199) 8）Jianye Cai#, Jiancheng Wang#, Yinong Huang#, Haoxiang Wu, Ting Xia, Jiaqi Xiao, Xiaoyong Chen, Hongyu Li, Yuan Qiu, Yingnan Wang, Tao Wang, Huimin Xia, and Qi Zhang*, Peng Xiang*. ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells. Cell Death Dis. 2016,7(11):e2459.(IF:5.638) 9）Jiang Y※, Zhang Q ※(co-first author), Hu Y, Li T, Yu J, Zhao L, Ye G, Deng H, Mou T, Cai S, Zhou Z, Liu H*, Chen G*, Li G*, Qi X*. ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer. Ann Surg. 2018 Dec 20. （IF:9.20） 10)Deng Y※, Cheng J※, Fu B, Liu W, Chen G, Zhang Q*, Yang Y*.Hepatic carcinoma-associated fibroblasts enhance immunosuppression by facilitating the generation of myeloid-derived suppressor cells. Oncogene. 2017, 36(8):1090-1101. (IF:6.854) 11)Li T※, Zhang Q※ (co-first author)，Jiang YM, Hu YF, Chen GH*, Li GX*. Gastric cancer cells inhibit natural killer cell proliferation and induced apoptosis via prostaglandin E2. Oncoimmunology, 2015;5(2): e1069936.（IF:5.503） 12)Cheng JT#, Deng YN#, Yi HM, Wang GY, Fu BS, Chen WJ, Liu W, Tai Y, Peng YW*and Zhang Q*.Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6 mediated STAT3 activation. Oncogenesis,.2016. 5:e198. （IF:4.722） 13)Zhang YC, Liu W, Fu BS, Wang GY, Li HB, Yi HM, Jiang N, Wang G, Zhang J, Yi SH, Li H, Zhang Q*, Yang Y*, Chen GH. Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation. Cytotherapy. 2017, 19(2):194-199. (IF:3.993) 14)Chen JJ, Cai N, Chen GZ, Jia CC, Qiu DB, Du C, Liu W, Yang Y, Long ZJ*, Zhang Q*. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma. Oncotarget.2017;8(11):17593-17609. (IF:5.168) 15)Deng YN, Yi SH, Wang GY, Cheng JT, Zhang YC, Chen WJ, Tai Y, Chen SH, Chen GH, Liu W, Zhang Q*, Yang Y*（共同通讯）.Umbilical Cord-Derived Mesenchymal Stem Cells Instruct Dendritic Cells to Acquire Tolerogenic Phenotypes through the IL-6-Mediated Upregulation of SOCS1, Stem Cells &Development, 2014,;23(17):2080-92. (IF:3. 315) 16)Jia CC, Wang TT, Liu W, Fu BS, Hua X, Wang GY, Li TJ, Li X, Wu XY, Tai Y, Zhou J, Chen GH, Zhang Q*. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion.PLoS One. 2013, 8(5):e63243.(IF: 2. 766) 17)Ye X, Guo Y, Zhang Q(共同第一作者), Chen W, Hua X, Liu W, Yang Y*, Chen G*βKlotho Suppresses Tumor Growth in Hepatocellular Carcinoma by Regulating Akt/GSK-3β/Cyclin D1 Signaling Pathway, PLoS One, 2013, 8(1), e55615. (IF 2.766); 18)Li T, Yi S, Liu W, Jia C, Wang G, Hua X, Tai Y, Zhang Q*, Chen G*（共同通讯）Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity. Med Oncol. 2013, 30(3):663-669.(IF:2.92) 19)Li T, Yang Y, Hua X, Wang G, Liu W, Jia C, Tai Y, Zhang Q*, Chen G*（共同通讯）.Hepatocellular Carcinoma-Associated Fibroblasts Trigger NK Cell Dysfunction via PGE2 and IDO, Cancer Lett, 2012, 318(2), 154-161.(IF: 6.49) 20)Pan GZ, Yang Y, Zhang J, Liu W, Wang GY, Zhang YC, Yang Q, Zhai FX, Tai Y, Liu JR, Zhang Q* and Chen GH*（共同通讯）.Bone marrow mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injuries via inactivation of the MEK/ERK signaling pathway in rats, J Surg Res, 2012, 178(2), 935-948.(IF: 2.051) 21)Wang GY, Yang Y, Li H, Zhang J, Li MR, Zhang Q*, Chen GH*（共同通讯）.Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4(+) CD25(+) Foxp3(+) regulatory T cell expansion, Hepatol Res, 2012, 42(2), 192-202,.(IF: 3.415) 22)Chen W, Wu Y, Liu W, Wang G, Wang X, Yang Y, Chen W, Tai Y, Lu M, Qian Q, Zhang Q*, Chen G*（共同通讯）.Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma,Cancer Lett, 2011, 307(1), 93-103.(IF”: 6.49) 23)Cai N, Xie SJ , Qiu DB, Jia CC, Du C, Liu W, Chen JJ*,Zhang Q*（共同通讯Potential effects of α-mangostin in the prevention and treatment of hepatocellular carcinoma.Journal of Functional Foods. 2016, 26:309-318.(IF: 3.47) 24)Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q* , Chen GH*（共同通讯）.A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation, PLoS One, 2011, 6(9), e25295.(IF: 2.766) 25)Lei J, Wang Z, Hui D, Yu W, Zhou D, Xia W, Chen C, Zhang Q, Wang Z, Zhang Q*, Xiang AP*（共同通讯）.Ligation of TLR2 and TLR4 on murine bone marrow-derived mesenchymal stem cells triggers differential effects on their immunosuppressive activity,Cell Immunol, 2011, 271(1), 147-156. (IF: 2.995) 26)ZHANG Q, YANG Y*, ZHANG J, WANG GY, LIU W, QIU DB, HEI ZQ, YING QL, CHEN GH*.Efficient derivation of functional hepatocytes from mouse induced pluripotent stem cells by a combination of cytokines and sodium butyrate, Chin Med J (Engl), 2011, 124, 3786-3793.(IF: 1.596) 27)ZHANG YC, ZHANG Q*, LI Hua, ZHANG J, WANG GS, XU C, YI SH, YI HM, CAI CJ, LU MQ, YANG Y , CHEN GH*(共同通讯作者).Prognostic factors for late mortality after liver transplantation for benign end-stage liver disease, Chin Med J (Engl), 2011, 124,4229-4235.(IF: 1.596) 28)Zhang Q*, Chen G*(cofirst author), Liu X, Qian Q. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res. 2007 Feb;17(2):89-99.(IF:15.393) 29)Zhang Q*, Nie M*(cofirst author), Sham J, Su C, Xue H, Chua D, Wang W, Cui Z, Liu Y, Liu C, Jiang M, Fang G, Liu X, Wu M, Qian Q. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combing with endostatin gene. Cancer Res.2004,64(15):5390-7.(IF 9.13) 30)Zhang Q*, Chen G * (cofirst author), Wang X, Peng L, Liu C, Yang Y,Su C, Wu H, Li L, Liu X, Wu M & Qian Q . Increased Safety with Preserved Antitumoral Efficacy on Hepatocellular Carcinoma with Dual-regulated Oncolytic Adenovirus. Clinical Cancer Research2006;12(21), 6523-6531 (IF 10.199) 31)Jiang M*, Shi W*, Zhang Q* (cofirst author), Wang X, Guo M, Cui Z, Su Ch, Yang Q, Li Y, Sham J, Liu X, Wu M, and Qian Q. Gene Therapy for Her2 over-expression cancers using adenovirus mediated full-length anti-Her2 antibody. Clinical Cancer Research，2006;12(20):6179-85. (IF 10.199) 1）“间充质干细胞在乙型肝炎相关性肝功不全的转化应用”，课题编号：2015B020226004，（2015年广东省前沿与关键技术创新专项（广东省干细胞重大科技专项），500万，2015.09-2018.09，项目负责人。 2）“线粒体自噬功能障碍修复在间充质干细胞减轻高龄供肝缺血再灌注损伤中的机制研究”，课题编号：81870449，国家自然科学基金-面上项目，57万元，2019.01 -2023.12，项目负责人。3）“MSC通过线粒体转运减轻肝脏缺血再灌注损伤的机制研究”，课题编号：81670601，国家自然科学基金-面上项目，58万元，2017.01 -2021.12，项目负责人。 4）“间充质干细胞对Toll样受体4信号通路负调控减轻肝脏缺血再灌注损伤的机制研究”，课题编号：81370555，国家自然科学基金-面上项目，70万元，2014.01 -2017.12，项目负责人。 5）“Toll样受体4信号通路在间充质干细胞减轻肝脏缺血再灌注损伤的作用及机制研究”，课题编号：141032，霍英东教育基金会第十四届高等院校青年教师基金基础性研究课题，2万美金，2014.3-2017.2，主持，排名第一。 6）“成纤维细胞直接再编程为肝干细胞的实验研究”，课题编号：81170452，国家自然科学基金-面上项目，55万，2012.01 -2015.12，项目负责人。 7）“人多能干细胞定向肝分化的调控机制及转化研究”，课题编号，S20120011190，广东省自然科学基金杰出青年基金项目，100万，2012.10-2016.10，项目负责人。 8）“应用人脐带间充质干细胞提高边缘性供肝利用率”，课题编号：2010J-E121，广州市科技计划支撑项目，15万，2010.10-2012.12，项目负责人。 9）“骨髓间充质干细胞在肝癌免疫微环境中的作用及机制研究”，课题编号：10151008901000208，广东省自然科学项目面上项目，5万， 2010.06-2012.06，项目负责人。 10）“肝脏疾病特异性诱导多能干细胞平台的建立及应用基础研究”，课题编号：2009B060700109，广东省科技计划项目，3万，2009.10-2012.12，项目负责人。 11）“探究人脐带间充质干细胞作为新型细胞免疫抑制剂的实验研究”，中山大学青年教师培育项目，15万，2009.10-2012.10，项目负责人。 12）“诱导多能干细胞（iPS）定向分化为肝细胞的研究”, 15万，课题编号：30801112, NCSF-青年科学基金， 2009.1-2011.12。 13）“靶向癌干细胞的基因-病毒治疗系统的研制”，60万，课题编号：200774, 教育部百篇优秀博士专项基金，2007.1-2011.12 。 |